psychopharmacology | CARLAT PUBLISHING

Psychopharm Commandment 3: Lithium Toxicity

October 10, 2022

Chris Aiken, MD and Kellie Newsome, PMHNP

Lithium toxicity: How to avoid it, and what to do when it happens.

CLINICAL UPDATE

Six Tips From Prescribing Psychotropics

August 1, 2022

Chris Aiken, MD

Chris Aiken, MD.

Editor-in-Chief of The Carlat Psychiatry Report. Practicing psychiatrist, Winston-Salem, NC.

Dr. Aiken, author for this educational activity, has no relevant financial relationship(s) with ineligible companies to disclose.

New answers to age-old questions, such as adjusting the dose to account for drug interactions, reducing side effects, maintaining weight, and protecting that finicky organ—the kidneys.

What Gets in the Way of Antidepressants?

August 1, 2022

Chris Aiken, MD and Garrett Rossi, MD.

Garrett Rossi, MD.
Inpatient/consult attending psychiatrist, AtlantiCare Regional Medical Center, Pomona, NJ.

Chris Aiken, MD.
Editor-in-Chief, The Carlat Psychiatry Report. Practicing psychiatrist, Winston-Salem, NC.

Dr. Rossi and Dr. Aiken, authors for this educational activity, have no relevant financial relationship(s) with ineligible companies to disclose.

Recent research has added to our understanding of factors that inhibit response to treatment, including major stress, nonadherence, and anxiety.

Quetiapine Reconsidered

June 1, 2022

Paul Riordan, MD.

Paul Riordan, MD. Assistant Consulting Professor of Psychiatry, Duke University. Dr. Riordan has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

It is the best of drugs; it is the worst of drugs. Quetiapine (Seroquel) has a few benefits that are unmatched by other medications, and here we explore where it fits in depression, bipolar, schizophrenia, as well as off-label uses like anxiety and sleep.

Real-World Alcohol Use Disorder Treatment

March 1, 2022

Ismene Petrakis, MD

Ismene Petrakis, MD

Addiction psychiatrist and professor at Yale School of Medicine. Chief of Mental Health, VA Connecticut Healthcare System, New Haven, CT.

Dr. Petrakis has disclosed that she participated in a study in which she did not receive any compensation from Alkermes apart from medication and Alkermes did not fund the study. Dr. Capurso has reviewed this material and found no evidence of bias pertaining to this educational activity.

Many patient with alcohol use disorder (AUD) also have comorbid psychiatric illness. Treating these patients can be challenging however there are evidenced based approaches that have been shown to be effective. Dr. Petrakis reviews the latest evidence in treating AUD in this challenging population.

Medications for Alcohol Use Disorder: An Overview

March 1, 2022

Mikveh Warshaw, NP.

Mikveh Warshaw, NP. Psychiatric mental health nurse practitioner, Community Health Center Inc. and faculty member of Center for Key Populations (CKP) Program, Middletown, CT. Ms. Warshaw has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

There are three FDA approved medications for alcohol use disorder (AUD) and many others that have been tested. Here, we summarize the evidence behind the various medications for alcohol use disorder and highlight clinical scenarios in which each should be considered.

Meds for Alcohol Use Disorders

January 18, 2022

Mikveh Warshaw, NP.

Mikveh Warshaw, NP. Ms. Warshaw has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Naltrexone has shown efficacy for the treatment of alcohol use disorder in tightly controlled trials. Here, researchers demonstrate the efficacy of naltrexone in a large scale naturalistic study.

How to Treat ADHD in Bipolar Disorder

November 5, 2021

Chris Aiken, MD.

Chris Aiken, MD. Editor-in-Chief of TCPR. Practicing psychiatrist, Winston-Salem, NC. Dr. Aiken has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Are stimulants risky in bipolar disorder? And which is safer – methylphenidate or amphetamine? Chris Aiken, MD, lays out a practical approach to the overlap of bipolar disorder and ADHD.

Brexpiprazole Ineffective in Mania

September 28, 2021

Richard Moldawsky, MD.

Richard Moldawsky, MD. Dr. Moldawsky has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Choosing an antipsychotic in bipolar disorder just got more complicated. This series of industry-sponsored trials reveals that their anti-manic activity may not be a class effect.

Intranasal Esketamine: New Hope for Suicidal Patients?

April 12, 2021

Victoria Hendrick, MD. and Daniel Carlat, MD

Victoria Hendrick, MD.

Editor in Chief, The Carlat Hospital Psychiatry Report. Chief, Inpatient Psychiatry, Olive View UCLA Medical Center.

Daniel Carlat, MD. Publisher, The Carlat Hospital Psychiatry Report. Dr. Hendrick and Dr. Carlat have disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Imagine a drug that resolves depression within hours in people at imminent risk of suicide. Esketamine may be such a drug — but is it a miracle cure? Here we look at the data and discuss the pros and cons of this new treatment.